EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV

Chang Li, Anna Kate Anderson, Hongjie Wang, Sucheol Gil, Jiho Kim, Lishan Huang, Audrey Germond, Audrey Baldessari, Veronica Nelson, Katharine J Bar, Christopher W Peterson, John Bui und 2 weitere

Molecular Therapy · 2023-04 · 31 (4) · 1059-1073

DOI: 10.1016/j.ymthe.2023.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2023-04. Verfasst von Chang Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA. Electronic address: cli1239@uw.edu. Hauptthemen laut MEDLINE: HIV Infections, Simian Immunodeficiency Virus, HIV-1, Simian Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aim to develop an in vivo hematopoietic stem cell (HSC) gene therapy approach for persistent control/protection of HIV-1 infection based on the stable expression of a secreted decoy protein for HIV receptors CD4 and CCR5 (eCD4-Ig) from blood cells. HSCs in mice and a rhesus macaque were mobilized from the bone marrow and transduced by an intravenous injection of HSC-tropic, integrating HDAd5/35++ vectors expressing rhesus eCD4-Ig. In vivo HSC transduction/selection resulted in stable serum eCD4-Ig levels of ∼100 μg/mL (mice) and >20 μg/mL (rhesus) with half maximal inhibitory concentrations (IC50s) of 1 μg/mL measured by an HIV neutralization assay. After simian-human-immunodeficiency virus D (SHIV.D) challenge of rhesus macaques injected with HDAd-eCD4-Ig or a control HDAd5/35++ vector, peak plasma viral load levels were ∼50-fold lower in the eCD4-Ig-expressing animal. Furthermore, the viral load was lower in tissues with the highest eCD4-Ig expression, specifically the spleen and lymph nodes. SHIV.D challenge triggered a selective expansion of transduced CD4+CCR5+ cells, thereby increasing serum eCD4-Ig levels. The latter, however, broke immune tolerance and triggered anti-eCD4-Ig antibody responses, which could have contributed to the inability to eliminate SHIV.D. Our data will guide us in the improvement of the in vivo approach. Clearly, our conclusions need to be validated in larger animal cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsSimian Immunodeficiency VirusHIV-1Simian Acquired Immunodeficiency SyndromeHumansAnimalsMiceMacaca mulattaHematopoietic Stem Cells

Stichwörter der Autor:innen

eCD4-Ig decoy receptorgene therapyhelper-dependent adenovirus vectorshematopoietic stem cellsin vivomobilizationrhesus macaquessimian-human immunodeficiency virus

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA. Electronic address: cli1239@uw.edu.
  • Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.
  • Washington National Primate Research Center, Division of Regenerative Medicine and Gene Therapy, Seattle, WA 98195, USA.
  • Stem and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Stem and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Washington National Primate Research Center, Division of Regenerative Medicine and Gene Therapy, Seattle, WA 98195, USA.

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NHLBI NIH HHS
  • Bill and Melinda Gates Foundation
  • National Institutes of Health
  • University of Washington
  • NHLBI

Zitieren

APA

Li, C., Anderson, A. K., Wang, H., Gil, S., Kim, J., Huang, L., Germond, A., Baldessari, A., Nelson, V., Bar, K. J., Peterson, C. W., Bui, J., Kiem, H. P., & Lieber, A. (2023). Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV. Molecular Therapy, 31(4), 1059-1073. https://doi.org/10.1016/j.ymthe.2023.02.002

Vancouver

Li C, Anderson AK, Wang H, Gil S, Kim J, Huang L, et al. Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV. Molecular Therapy. 2023;31(4):1059-1073. doi:10.1016/j.ymthe.2023.02.002

BibTeX
@article{Li2023,
  author = {Li, Chang and Anderson, Anna Kate and Wang, Hongjie and Gil, Sucheol and Kim, Jiho and Huang, Lishan and Germond, Audrey and Baldessari, Audrey and Nelson, Veronica and Bar, Katharine J and Peterson, Christopher W and Bui, John and Kiem, Hans-Peter and Lieber, André},
  title = {Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV},
  journal = {Molecular Therapy},
  year = {2023},
  volume = {31},
  number = {4},
  pages = {1059--1073},
  doi = {10.1016/j.ymthe.2023.02.002}
}
Kostenlos starten →